AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1015 participants.
Also called NCT03192215
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 1,015 participants
- Sponsor
- Registry
-
NCT03192215
-
- Other papers using this trial's data
- Apixaban Versus Aspirin to Reduce Cognitive Decline After Cryptogenic Stroke and Atrial Cardiopathy: ARCADIA-Cognition Study
- Apixaban to Prevent Covert Infarcts After Cryptogenic Stroke in Patients With Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Randomized Clinical Trial
- Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke: A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial
- Diagnosis of Incident Cancer After Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized Trial
- History of Cancer and Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Clinical Trial
- Hypertension With High-Risk Features in Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized Clinical Trial
- Premature Atrial Contractions as a Marker of Atrial Cardiopathy: A Revised Analysis of the ARCADIA Randomized Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Terminated
Technical summary
Registry record NCT03192215. Randomized; quadruple masking; primary purpose prevention. Start 2018-01-19 (actual); primary completion 2023-03-31 (actual). Results posted on 2025-04-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
- Acronym
- ARCADIA
- Condition
- Stroke
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Aspirin
- Lead sponsor
- Columbia University
- Collaborator
- National Institute of Neurological Disorders and Stroke (NINDS)
- Collaborator
- University of Cincinnati
- Collaborator
- Medical University of South Carolina
- Collaborator
- Bristol-Myers Squibb
- Collaborator
- Pfizer
- Collaborator
- Roche Pharma AG
- Collaborator
- Weill Medical College of Cornell University
- Collaborator
- University of Washington
Record details
- Record id
cardio:ct-nct03192215- Content hash
1900de817370977648e43fa5569794857e39043492d52789d1ed3153d91215dc